NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve use of biomarkers in manage¬ment of prostate cancer, optimization of radiotheranostics in patients with prostate cancer, employment of molecular markers in prostate cancer, and management of metastatic hormone-sensitive pros¬tate cancer (mHSPC). After hearing and assimilating this program, the clinician will be better able to:
1. Use prostate-specific antigen tests for early detection of prostate cancer.
2. Differentiate activities of α-emitters from those of ß-emitters.
3. Compare various molecular markers used in prostate cancer.
4. Compare de novo metastatic prostate cancer with recurrent disease.
5. Outline the mutational landscape of prostate cancer.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Urology
- Start Date: 2022-06-08 05:00:00
- End Date: 2022-06-08 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all